tirzepatide and cardiovascular outcomes Original Article: Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes (SURPASS-CVOT)

Tirzepatide linked to lower risk for death, adverse CV and kidney outcomes vs. GLP-1s

27.32

★★★★☆4.8 (126)

💉 In a large real-world study, tirzepatide was associated with a lower incidence of major cardiovascular outcomes vs semaglutide: 📊 Composite CV outcome: 1.90% vs 2.18% (HR 0.86, p=0.01) ❤️ New-onset heart

21.87

★★★★★4.9 (98)

Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes @NEJM Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to a composite of

26.00

★★★★★5.0 (157)

Tirzepatide and the 10‐year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year SURMOUNT‐1 trial - Hankosky

23.98

★★★★★4.7 (84)

Tirzepatide vs Dulaglutide for Cardiovascular Outcomes (SURPASS-CVOT) | NEJM

24.58

★★★★★4.9 (203)

Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial

22.19

★★★★★5.0 (176)

Long-awaited SURPASS-CVOT: Cardiovascular Outcomes with Tirzepatide vs Dulaglutide in NEJM: #tirzepatide noninferior to #dulaglutide for 3-point MACE in T2D with ASCVD, with greater improvements in weight, A1c, BP, triglycerides, and kidney function

28.81

★★★★★4.8 (132)